Correlation analysis of ApoA1 and ApoB and executive function in different stages of Alzheimer's disease

Lei CHEN, Qiansen FENG, linlin LI, Ziqi WANG

Chinese Journal of Alzheimer's Disease and Related Disorders ›› 2025, Vol. 8 ›› Issue (3) : 170-174.

PDF(911 KB)
Home Journals Chinese Journal of Alzheimer's Disease and Related Disorders
Chinese Journal of Alzheimer's Disease and Related Disorders

Abbreviation (ISO4): Chinese Journal of Alzheimer's Disease and Related Disorders      Editor in chief: Jun WANG

About  /  Aim & scope  /  Editorial board  /  Indexed  /  Contact  / 
PDF(911 KB)
Chinese Journal of Alzheimer's Disease and Related Disorders ›› 2025, Vol. 8 ›› Issue (3) : 170-174. DOI: 10.3969/j.issn.2096-5516.2025.03.003
Research Articles

Correlation analysis of ApoA1 and ApoB and executive function in different stages of Alzheimer's disease

Author information +
History +

Abstract

Objective: To explore the relationship between apolipoprotein A1 (ApoA1), apolipoprotein B (ApoB) and executive function in people with early cognitive impairment (EMCI), late mild cognitive impairment (LMCI), and early Alzheimer's disease (AD) patients, and to establish a group of Normal Control (NC) as a control group, in order to provide help for clinical intervention in the AD patients. Methods: A total of 142 people aged 50-80 years were recruited from Chengdu Fourth People's Hospital, including 35 cases of EMCI, 17 cases of LMCI, 26 cases of AD and 64 cases of NC. Each patient collected the following scales for executive function assessments using The Shape Trail Test part A (STT-A), The Shape Trail Test part B (STT-B), The Animal Fluency Test (AFT), The Symbol Digit Modalities Test (SDMT), Digit Span Test (DST) at baseline. The laboratory collected morning fasting blood to detect ApoA1 and ApoB levels. Spearman correlation test was used to analyze the correlation between ApoA1, ApoB and executive function, and linear regression analysis of the influencing factors of ApoA1 and ApoB on executive function. Results: The years of education in AD group were significantly lower than that in the NC group (P<0.05); In the NC group,the time spent on STT-A and STT-B were significantly lower than that in the EMCI group, LMCI group and AD group(P<0.05); in the EMCI group, the time spent on STT-A was significantly lower than that in the AD group(P<0.05), and the AFT and SDMT scores were significantly lower than those in the NC group(P<0.05) ; in the AD group, the AFT score was significantly lower than that in the NC group and LMCI group(P<0.05) ; the SDMT and DST score was significantly lower than that in the NC group (P<0.05) ; the ApoA1 level in the AD group was significantly lower than that in the NC group and EMCI group(P<0.05) ; there was no statistically significant difference in the ApoB levels among the four groups. ApoA1 levels were positively correlated with AFT, SDMT, and DST (P<0.05), and negatively correlated with STT-A and STT-B (P<0.05) ; ApoB levels had no correlation with executive functions; after adjusting for confounding factors, the multiple linear regression results of ApoA1 and executive function showed that ApoA1 significantly positively affected SDMT (P<0.05). After diagnosis stratification, the results of linear regression between ApoA1 and SDMT showed that ApoA1 could significantly positively affect SDMT in the NC group, LMCI group, and AD group (P<0.05). Conclusion: The connection between ApoB and executive function has not been found;. ApoA1 is mainly significantly related to information processing speed in the NC group, LMCI group, and AD group, indicating that the combination of ApoA1 and information processing speed can become an important tool for exploring cognitive impairment..

Key words

Early mild cognitive impairment / Late mild cognitive impairment / Alzheimer's disease / Executive function / Apolipoproteins

Cite this article

Download Citations
Lei CHEN , Qiansen FENG , linlin LI , et al. Correlation analysis of ApoA1 and ApoB and executive function in different stages of Alzheimer's disease[J]. Chinese Journal of Alzheimer's Disease and Related Disorders. 2025, 8(3): 170-174 https://doi.org/10.3969/j.issn.2096-5516.2025.03.003

References

[1]
王刚, 齐金蕾, 刘馨雅, 等. 中国阿尔茨海默病报告2024[J]. 诊断学理论与实践, 2024, 23(3):219-256.
[2]
Ren R, Qi J, Lin S, et al. The china Alzheimer report 2022[J]. Gen Psychiatr, 2022, 35(1): 1-19.
[3]
Marshall GA, Rentz DM, Frey MT, et al. Executive function and instrumental activities of daily living in mild cognitive impairment and Alzheimer's disease[J]. Alzheimers Dement, 2011, 7(3): 300-308.
[4]
Kim SJ, Park JK, Yeo MS, et al. Dual-task-based music therapy to improve executive functioning of elderly patients with early stage Alzheimer's disease: a multiple case study[J]. Int J Environ Res Public Health, 2022, 19(19).
[5]
Zhang W, Low LF, Schwenk M, et al. Review of gait, cognition, and fall risks with implications for fall prevention in older adults with dementia[J]. Dement Geriatr Cogn Disord, 2019, 48(1-2): 17-29.
[6]
Zhu W, Xu L, Zhang H, et al. Elevated plasma free fatty acid susceptible to early cognitive impairment in type 2 diabetes mellitus[J]. J Alzheimers Dis, 2021, 82(3): 1345-1356.
[7]
PokhareLY, Mouhanna F, Nambi V, et al. ApoB, small-dense LDL-C, Lp(a), LpPLA2 activity, and cognitive change[J]. Neurology, 2019, 92(22): e2580-e2593.
[8]
Jessen f, Wolfsgruber S, Wiese B, et al. AD dementia risk in late MCI, in early MCI, and in subjective memory impairment[J]. Alzheimers Dement, 2014, 10(1): 76-83.
[9]
Loewenstein DA, Greig MT, Schinka JA, et al. An investigation of PreMCI: subtypes and longitudinal outcomes[J]. Alzheimers Dement, 2012, 8(3): 172-179.
[10]
Boiko AS, Mednova IA, Kornetova EG, et al. Apolipoprotein serum levels related to metabolic syndrome in patients with schizophrenia[J]. Heliyon, 2019, 5(7): e02033.
[11]
Lefterov I, Fitz NF, Cronican AA, et al. Apolipoprotein A-I deficiency increases cerebral amyloid angiopathy and cognitive deficits in APP/PS1DeltaE9 mice[J]. J Biol Chem, 2010, 285(47): 36945-36957.
[12]
Lewis TL, Cao D, Lu H, et al. Overexpression of human apolipoprotein A-I preserves cognitive function and attenuates neuroinflammation and cerebral amyloid angiopathy in a mouse model of Alzheimer disease[J]. J Biol Chem, 2010, 285(47): 36958-36968.
[13]
谢东平. 血脂与轻度认知功能障碍、痰瘀证的相关性研究[D]. 广州: 广州中医药大学, 2005.
[14]
Slot RE, Van Harten AC, Kester MI, et al. Apolipoprotein A1 in cerebrospinal fluid and plasma and progression to Alzheimer's disease in non-demented elderly[J]. J Alzheimers Dis, 2017, 56(2): 687-697.
[15]
Li X, Salami A, Persson J, et al. Hub architecture of the human structural connectome: links to aging and processing speed[J]. Neuroimage, 2023, 278.
[16]
Puzianowska-Kuźnicka M, Owczarz M, Wieczorowska-Tobis K, et al. Interleukin-6 and C-reactive protein, successful aging, and mortality: the polsenior study[J]. Immun Ageing, 2016, 13: 21.
[17]
Löffler T, Flunkert S, Havas D, et al. Impact of ApoB-100 expression on cognition and brain pathology in wild-type and hAPPsl mice[J]. Neurobiol Aging, 2013, 34(10): 2379-2388.
[18]
Hu H, Tan L, Bi YL, et al. Association of serum apolipoprotein B with cerebrospinal fluid biomarkers of Alzheimer's pathology[J]. Ann Clin Transl Neurol, 2020, 7(10): 1766-1778.
PDF(911 KB)

Accesses

Citation

Detail

Sections
Recommended

/